凌源钢铁股份有限公司 董事会薪酬与考核委员会关于公司 2024 年限制性股票激励 （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形。 范性文件和《公司章程》规定的任职资格，符合《管理办法》规定的激励对象条 件，符合《凌源钢铁股份有限公司 2024 年限制性股票激励计划（草案）》（以 下简称"《激励计划（草案）》"）规定的激励对象范围，其作为公司本次激励 计划预留授予激励对象的主体资格合法、有效。 不得成为激励对象的情形： （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； 计划预留授予激励对象名单的核查意见（截至预留授予日） 凌源钢铁股份有限公司（以下简称"公司"）董事会薪酬与考核委员会依据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简 称"《管理办 ...

Core Viewpoint - The company has adjusted the grant price of its 2022 restricted stock incentive plan from 25.0725 CNY per share to 23.5992 CNY per share due to the implementation of its 2024 annual profit distribution plan [1][9][11] Summary by Sections Adjustment Details - The adjustment of the grant price is a result of the company's 2024 annual profit distribution, which involved a cash dividend of 1.50 CNY per share, totaling 116.8025 million CNY [9] - The adjusted grant price calculation follows the formula: P = P0 - V, where P0 is the original grant price and V is the cash dividend per share [9] - The new grant price after adjustment is calculated as 25.0725 CNY - 1.4733 CNY = 23.5992 CNY per share [9] Decision-Making Process - The adjustment was approved during the third meeting of the third board of directors and the supervisory board on August 8, 2025 [1][8] - The decision followed the necessary procedures, including independent opinions from the board and supervisory committee [10][11] Impact on the Company - The adjustment of the grant price is not expected to have a substantial impact on the company's financial status or operational results [9] - The stability of the management team and the continuation of the incentive plan are not affected by this adjustment [9] Opinions from Supervisory and Compensation Committees - The supervisory board and the compensation and assessment committee both agree that the adjustment complies with relevant laws and regulations and does not harm the interests of the company or its shareholders [10][11]

Core Viewpoint - The legal opinion letter addresses the adjustments to the grant price, the achievement of vesting conditions for the first grant's third vesting period, and the cancellation of certain restricted stocks related to Hangzhou Aotai Biotechnology Co., Ltd.'s 2022 restricted stock incentive plan [1][4][23] Summary by Relevant Sections Legal Framework and Compliance - The law firm conducted its review based on the Company Law, Securities Law, and relevant regulations, ensuring that all documents provided by the company were authentic, accurate, and complete [2][3][4] - The law firm confirmed that the legal opinions provided are based solely on current Chinese laws and do not extend to any foreign laws [4][5] Incentive Plan Adjustments - The grant price for the incentive plan was adjusted from 51.00 CNY per share to 28.0067 CNY per share, and the number of shares granted was increased from 770,000 to 1,132,516 shares [10][12] - The adjustments were deemed to comply with the relevant regulations and did not harm the interests of the company or its shareholders [10][14] Vesting Conditions - The first grant's third vesting period and the reserved grant's second vesting period have been confirmed to meet the necessary conditions, allowing 94 eligible participants to vest a total of 409,472 shares, while 18 reserved participants can vest 29,418 shares [15][22] - The vesting conditions were verified against the company's performance metrics, which included revenue and product registration targets [21][22] Cancellation of Restricted Stocks - The company plans to cancel a total of 6,177 shares of restricted stock that were granted to three participants who left the company, in accordance with the incentive plan's provisions [22][23] - The cancellation process was confirmed to be compliant with the relevant regulations and did not adversely affect the interests of the company or its shareholders [23]

Group 1 - The company has announced the allocation of stock options and restricted stocks under its incentive plan, with a total of 1,899.909 million stock options and 1,481.097 million restricted stocks being granted [1] - The distribution of stock options includes 594.21 million for directors and senior management, accounting for 31.28% of the total options granted, and 1,155.699 million for other key personnel, representing 60.83% [1] - The allocation of restricted stocks shows that 110.23 million are granted to directors and senior management, which is 7.44% of the total restricted stocks, while 1,220.867 million are allocated to other key personnel, making up 82.43% [1] Group 2 - The total number of stock options and restricted stocks granted does not exceed 1% of the company's total share capital, and the cumulative number of stocks involved in all effective incentive plans will not exceed 20% of the company's total share capital [1]

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that the adjustments to the 2021 and 2024 restricted stock incentive plans of Kewei Medical Technology Co., Ltd. comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][10][13]. Approval and Authorization - The company held its first board meeting on December 5, 2021, where it approved the draft of the 2021 restricted stock incentive plan and related matters [4][5]. - The company convened its second extraordinary general meeting on December 21, 2021, to approve the 2021 restricted stock incentive plan [6]. - On April 24, 2023, the company approved adjustments to the 2021 restricted stock incentive plan during its board and supervisory board meetings [6][7]. - The company held its second board meeting on March 1, 2024, to approve the draft of the 2024 restricted stock incentive plan [8][9]. Adjustment of Related Matters - The company held its 2024 annual general meeting on May 21, 2024, where it approved a cash dividend distribution of 12 yuan per 10 shares, totaling approximately 244 million yuan [10]. - The adjustments to the grant prices of the restricted stocks for both the 2021 and 2024 incentive plans were made in accordance with the provisions regarding capital increases and dividend distributions [11][12]. Conclusion - The legal opinion asserts that the adjustments to the 2021 and 2024 incentive plans are in compliance with the relevant laws and regulations, ensuring the legality and validity of the actions taken by the company [13].

Core Points - The company, 科瑞技术 (002957.SZ), has disclosed a draft for its 2025 stock option and restricted stock incentive plan, proposing to grant a total of 1.1782 million stock options, which accounts for approximately 0.28% of the company's total share capital at the time of the announcement [1] - The plan also includes granting a total of 589,100 restricted shares, representing about 0.14% of the company's total share capital at the time of the announcement [1] - The exercise price for the stock options is set at 12.63 yuan per share, while the grant price for the restricted shares is 8.42 yuan per share [1] - A total of 104 individuals, primarily core employees from the company and its subsidiaries, will be the recipients of the incentive plan, excluding directors, supervisors, and senior management [1] - The validity period for the stock option incentive plan is from the completion of the stock option grant registration until all options are exercised or canceled, with a maximum duration of 36 months; the restricted stock incentive plan has a similar validity period [1]

Core Points - The company, Keri Technology (002957.SZ), has disclosed a draft for its 2025 stock option and restricted stock incentive plan [1] - The plan includes granting a total of 1.1782 million stock options, accounting for approximately 0.28% of the company's total share capital at the time of the announcement [1] - Additionally, the plan proposes granting a total of 589,100 restricted stocks, which represents about 0.14% of the company's total share capital at the time of the announcement [1] Stock Options and Restricted Stocks - The exercise price for the stock options is set at 12.63 yuan per share, while the grant price for the restricted stocks is 8.42 yuan per share [1] - A total of 104 individuals, primarily core employees from the company and its subsidiaries, will be granted these incentives, excluding directors, supervisors, and senior management [1] Duration of the Incentive Plan - The validity period for the stock option incentive plan is from the completion of the stock option grant registration until all options are exercised or canceled, with a maximum duration of 36 months [1] - The validity period for the restricted stock incentive plan is from the completion of the restricted stock grant registration until all granted restricted stocks are fully released from restrictions or repurchased, also with a maximum duration of 36 months [1]

Core Viewpoint - The company has adjusted the grant price and quantity of the 2023 restricted stock incentive plan due to the implementation of the 2024 profit distribution and capital reserve transfer plan [1][6]. Group 1: Decision Process and Disclosure - The board of directors approved the adjustment of the grant price and quantity of the incentive plan, following the relevant regulations and authorization from the shareholders' meeting [1][2]. - The independent directors provided independent opinions on the related proposals, confirming the legitimacy of the grant conditions and the qualifications of the incentive objects [3][6]. Group 2: Adjustment Details - The adjustment was necessitated by the profit distribution and capital reserve transfer plan, which involved a cash dividend of 5 yuan per 10 shares and a capital reserve transfer of 4 shares for every 10 shares [4][5]. - The adjusted grant price is calculated to be 35.86 yuan per share, based on the formula considering the capital reserve transfer and cash dividends [5]. - The number of restricted stocks granted but not yet vested has been adjusted to 300,815 shares, reflecting a 40% increase from the previous quantity [5]. Group 3: Impact and Opinions - The adjustments to the grant price and quantity will not have a substantial impact on the company's financial status and operating results [6]. - The remuneration and assessment committee of the board agreed that the adjustments comply with relevant regulations and do not harm the interests of the company and its shareholders [6]. Group 4: Legal Opinions - The adjustments have received the necessary approvals and are in accordance with the relevant management regulations and listing rules [6].

Somore 山东松茂律师事务所 法律意见书 山东松茂律师事务所 关于泰和新材集团股份有限公司 第一个限售期解除限售条件成就相关事项的 法律意见书 致:泰和新材集团股份有限公司 山东松茂律师事务所（以下简称"本所"）是具有中华人民共和 国（以下简称"中国"）法律执业资格的律师事务所。根据泰和新材 集团股份有限公司（以下简称"泰和新材"或"公司"）与本所签订 的法律服务协议，本所就泰和新材 2022 年限制性股票激励计划预留 授予部分（以下简称"本激励计划"）第一个限售期解除限售（以下 简称"本次解除限售")相关事项出具本法律意见书。 本所依据《中华人民共和国公司法》(以下简称《公司法》)、《中 华人民共和国证券法》(以下简称《证券法》)、中国证券监督管理委 员会(以下简称"中国证监会")《上市公司股权激励管理办法》(以 下简称《管理办法》)、深圳证券交易所(以下简称"深交所")《深 圳证券交易所股票上市规则》(以下简称《上市规则》)、《深圳证券 交易所上市公司自律监管指南第 1 号——业务办理》（以下简称《自 律监管指南》）及适用的其他中国法律、行政法规、部门规章、规范 性文件(以下合称"中国法律")的规定， ...

证券代码：002326 证券简称：永太科技 公告编号：2025-063 浙江永太科技股份有限公司 票数量为 4,454,841 股，占目前公司总股本的 0.48%。 浙江永太科技股份有限公司（以下简称"公司"）于 2025 年 7 月 31 日召开 了第七届董事会第二次会议，审议通过了《关于公司 2024 年限制性股票激励计 划第一个解除限售期解除限售条件成就的议案》，认为公司 2024 年限制性股票 激励计划（以下简称"本次激励计划"）第一个解除限售期解除限售条件已经成 就，同意公司按照《浙江永太科技股份有限公司 2024 年限制性股票激励计划》 （以下简称"《2024 年激励计划》"）相关规定办理本次解除限售的相关事宜。 根据公司 2024 年第二次临时股东大会的授权，公司董事会办理了本次激励计划 第一个解除限售期解除限售股份的上市流通手续，现将相关事项公告如下： 一、本次激励计划简述及已履行的程序 公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2024 年限制性股票激励计划实施考核管理办法>的议案》及《关于提请股东大会授权 董事会办理股权激励相关事宜的议案》，上海市锦天城律师 ...